Is it Feasible to Completely Prevent Diabetic Kidney Disease?

When SGLT2Is were first introduced as hypoglycemic agents during the year 2008, no body was aware about their protective action on the heart, kidney, and retina of patients suffering type 2 diabetes mellitus (T2DM). SGLT2Is have revolutionized the treatment of T2DM patients with established or at risk for diabetic kidney disease (DKD). When Dapagliflosin was studied in T2DM patients with estimated glomerular filtration rate [eGFR] >90 mL/min/1.73m2, and normal urine albumin excretion, these cases were still susceptible to develop the renal end points. These results have raised the question about the ideal time to use SGLT2Is to completely abort the incidence of DKD. This review will try to answer this question.